Zina Saleam Huntush (1)
The most prevalent birth abnormality, congenital heart disease (CHD), affects 9.4 out of 1000 babies, Certain medications, such as phenytoin, lithium, amphetamines, warfarin, oestrogen, or progesterone, have been shown to raise the risk of congenital heart disease in offspring when used by the mother during pregnancy. Identify the incidence of Congenital Heart Disease in pediatric Following Maternal Use of luteal supportive Hormonal Therapy During Pregnancy. Retrospective research was conducted at a private cardiologist's clinic between February 12 and May 1, 2025. A pre-tested questionnaire was used to interview the mother or caregiver of each kid. It asked about the mother's medical history about associated conditions, the child's sociodemographics, and whether the mother had taken luteal supporting hormone during pregnancy. The kind of CHD and the history of progesterone usage (time, duration, and route) were ascertained by echo. This study regarding socio-demographic characteristics and showed that females were more than males (55%, 45%, respectively), found that 71.76% of the patients were under one year old, VSD was the most prevalent kind of CHDs in this study (28% of the cases), also, study reflect positive correlation between progesterone and CHD. Conclude of study result most of child with CHD was less than 1 years in age and there is associate between maternal progesterone intake and fetus born with CHD.
Highlights:
] Y. Liu, S. Chen, L. Zühlke, G. C. Black, M. K. Choy, N. Li, and B. D. Keavney, “Global birth prevalence of congenital heart defects 1970–2017: updated systematic review and meta-analysis of 260 studies,” Int. J. Epidemiol., vol. 48, no. 2, pp. 455–463, Apr. 2019.
[2] P. Khairy, R. Ionescu-Ittu, A. S. Mackie, M. Abrahamowicz, L. Pilote, and A. J. Marelli, “Changing mortality in congenital heart disease,” J. Am. Coll. Cardiol., vol. 56, no. 14, pp. 1149–1157, Sep. 2010.
[3] K. K. Stout et al., “2018 AHA/ACC Guideline for the Management of Adults with Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines,” J. Am. Coll. Cardiol., vol. 73, pp. e81–e192, 2019.
[4] V. Regitz-Zagrosek et al., “2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy,” Eur. Heart J., vol. 39, pp. 3165–3241, 2018.
[5] L. E. Schlichting, T. Z. Insaf, A. N. Zaidi, G. K. Lui, and A. R. Van Zutphen, “Maternal comorbidities and complications of delivery in pregnant women with congenital heart disease,” J. Am. Coll. Cardiol., vol. 73, pp. 2181–2191, 2019.
[6] R. M. Hayward, E. Foster, and Z. H. Tseng, “Maternal and fetal outcomes of admission for delivery in women with congenital heart disease,” JAMA Cardiol., vol. 2, pp. 664–671, 2017.
[7] K. Rakusan, “Drugs in pregnancy: implications for a cardiologist,” Exp. Clin. Cardiol., vol. 15, no. 4, pp. e100, 2010.
[8] S. J. Beardsley, I. Dostal, J. Cole, A. Gutierrez, and J. Robson, “Valproate use in women aged 15–44 years: an observational study in general practice,” BJGP Open, vol. 5, no. 2, Apr. 2021.
[9] R. M. Kliegman et al., Nelson Textbook of Pediatrics: Epidemiology and Genetic Basis of Congenital Heart Disease, Philadelphia, PA: Elsevier Inc., 2020, p. 9336.
[10] M. S. Balat and S. K. Sahu, “Congenital heart disease: Factors affecting it and role of RBSK India linking with situation,” Int. J. Community Med. Public Health, vol. 5, pp. 4437–4440, 2018.
[11] R. M. Kliegman et al., Nelson Textbook of Pediatrics: Epidemiology and Genetic Basis of Congenital Heart Disease, Philadelphia, PA: Elsevier Inc., 2020, p. 9345.
[12] J. W. Dreier, A. M. Andersen, and G. Berg-Beckhoff, “Systematic review and meta-analyses: Fever in pregnancy and health impacts in the offspring,” Pediatrics, vol. 133, pp. e674–e688, 2014.
[13] A. Miyake, T. Aono, T. Kinugasa, O. Tanizawa, and K. Kurachi, “Suppression of serum levels of luteinizing hormone by short-and long-loop negative feedback in ovariectomized women,” J. Endocrinol., vol. 80, pp. 353–356, 1979, doi: 10.1677/joe.0.0800353.
[14] M. Zaqout et al., “The impact of oral intake of dydrogesterone on fetal heart development during early pregnancy,” Pediatr. Cardiol., vol. 36, pp. 1483–1488, 2015.
[15] L. Li et al., “The maternal drug exposure birth cohort (DEBC) in China,” Nat. Commun., vol. 15, p. 5312, 2024.
[16] H. S. Tuky, M. K. Alghanimi, and B. A. Semender, “Comparing certain echocardiographic measurements with catheterization in children with pulmonary hypertension due to left-to-right cardiac shunt,” Med. J. Babylon, vol. 17, pp. 79–83, 2020.
[17] M. Mecklin, P. Heikkilä, and M. Korppi, “Low age, low birthweight and congenital heart disease are risk factors for intensive care in infants with bronchiolitis,” Acta Paediatr., vol. 106, pp. 2004–2010, 2017.
[18] F. J. Al-Dalla Ali, M. D. Hammood, K. M. Al-Dulaimy, and B. M. Salman, “Pattern of congenital heart disease among children referred for echocardiography in Ramadi city, West of Iraq,” ANB Med. J., vol. 15, pp. 40–44, 2019.
[19] Z. L. Steinberg, C. P. Dominguez-Islas, C. M. Otto, K. K. Stout, and E. V. Krieger, “Maternal and fetal outcomes of anticoagulation in pregnant women with mechanical heart valves,” J. Am. Coll. Cardiol., vol. 69, pp. 2681–2691, 2017.
[20] M. Zaqout et al., “The impact of oral intake of dydrogesterone on fetal heart development during early pregnancy,” Pediatr. Cardiol., vol. 36, pp. 1483–1488, 2015.
[21] H. H. Chou et al., “Association of maternal chronic disease with risk of congenital heart disease in offspring,” CMAJ, vol. 188, pp. e438–e446, 2016.
[22] S. Liu et al., “Association between maternal chronic conditions and congenital heart defects: a population‐based cohort study,” Circulation, vol. 128, pp. 583–589, 2013.
[23] G. Koren, Y. Barer, and A. Ornoy, “Fetal safety of methylphenidate – A scoping review and meta-analysis,” Reprod. Toxicol., vol. 93, pp. 230–234, 2020.
[24] S. Harlap, R. Prywes, and A. M. Davies, “Birth defects and oestrogens and progesterones in pregnancy,” Lancet, vol. 305, no. 7908, pp. 682–683, Mar. 1975.
[25] M. M. Amorim, M. H. da Silva Bastos, and L. Katz, “Mistreatment during childbirth,” Lancet, vol. 396, no. 10254, p. 816, Sep. 2020.
[26] C. Heneghan et al., “Oral hormone pregnancy tests and the risks of congenital malformations: a systematic review and meta-analysis,” F1000Research, vol. 7, p. 1725, 2019.
[27] A. Oberoi, N. Udgiri, and S. Bianca, “Drug use during pregnancy: are risk classifications more dangerous than the drugs?,” Lancet, vol. 362, pp. 330, Jul. 2003.
[28] I. Lacroix, C. Damase-Michel, M. Lapeyre-Mestre, and J. L. Montastruc, “Prescription of drugs during pregnancy in France,” Lancet, vol. 356, no. 9243, pp. 1735–1736, Nov. 2000.